Answers are grounded in this paper and cite their sources.
This multicenter retrospective study evaluated the clinicopathological features, prognostic factors, and evolution of rheumatoid arthritis-associated lymphoproliferative disorders (RA-LPD) treatment in the biologic and targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) era. We analyzed 217 patients diagnosed at eight Japanese institutions. Spontaneous regression was observed in 30.4% of patients with RA-LPD. Extranodal involvement was significantly more common in diffuse large B-cell lymphoma (DLBCL)-type, whereas Epstein-Barr virus positivity was higher in classical Hodgkin lymphoma (CHL)-type. DLBCL-type demonstrated superior progression-free survival (PFS) compared to CHL-type, while overall survival (OS) was comparable. Histological subtype was the sole independent predictor of PFS. Multivariate analysis identified low hemoglobin levels, elevated lactate dehydrogenase levels, and poor performance status as independent adverse prognostic factors for OS. Post-LPD diagnosis, methotrexate was discontinued in most patients, followed by an increased use of b/tsDMARDs. Transitioning to b/tsDMARDs represents a feasible strategy to balance RA control and oncological safety.
No takes yet. Share an insight, caveat, or question.
Okazaki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: